Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | GRM8 | O00222 | 2/20 | 0.35 |
| ▸ | GRM6 | O15303 | 2/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.35 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mandelic Acid SCHEMBL2760726 | 1.00 | LMNA (0.40) | LMNAMAPK1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2114569 | 0.84 | CHRNB4 (0.48) | LMNACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1711411 | 0.84 | CHRNB4 (0.48) | LMNACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL4873027 | 0.84 | CHRNB4 (0.48) | LMNACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL16105229 | 0.84 | CHRNB4 (0.48) | LMNACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2760561 | 0.84 | CHRNB4 (0.48) | LMNACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2760982 | 0.84 | CHRNB4 (0.48) | LMNACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1292916 | 0.84 | CHRNB4 (0.48) | LMNACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1292952 | 0.84 | CHRNB4 (0.48) | LMNACHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL1292998 | 0.83 | CHRNB4 (0.47) | LMNACHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534667-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2010-12-15 | — | — | EP | disclosed |
| US-7160922-B2 | Hemihydrate of a selective functional M1 muscarine receptor agonist | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060122280-A1 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122280-A1 | Muscarinic agonists | CHRM3, CHRM4, CHRM5 | LMNA 3527/4885MAPK1 3338/4885CHRNB2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.